#1 Clinical Trials Search in Europe

Find clinical trials in your area

Search by disease and location to discover available clinical trials matching your criteria.

↓

Matched clinical trials

  • A study to test the safety and effectiveness of ONA-255 in patients with advanced cancer including breast cancer and gastric cancer

    Recruiting

    2 1 1
    Investigated diseases:
    Spain

  • A Study Comparing GDC-4198 Alone and with Giredestrant versus Abemaciclib with Giredestrant for Advanced Breast Cancer After Previous CDK4/6 Treatment

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

  • A Study of Disitamab Vedotin for Adults with HER2 Expressing Advanced Breast Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    Germany Italy Spain

  • A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark France +8

  • A Study of Zanidatamab for Patients with Previously Treated HER2-Expressing Solid Tumors

    Recruiting

    2 1 1
    Investigated drugs:
    Spain

  • Maintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer

    Recruiting

    3 1 1
    Investigated drugs:
    Belgium Finland France Germany Italy Poland +1

  • Study of inavolisib, ribociclib, and fulvestrant for patients with advanced hormone-receptor-positive, HER2-negative breast cancer.

    Recruiting

    2 1 1
    Investigated drugs:
    France Germany Italy Poland Spain

  • Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany Spain

  • Study of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Germany Italy The Netherlands +2

  • Study of inavolisib and fulvestrant for patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Spain